Leading Alzheimer’s Researchers Coming to New Orleans for GAP-Net Site Optimization Conference  

Researchers and Executives from more than 100+ Alzheimer’s and Parkinson’s clinical trial sites to collaborate on finding a cure for the devastating diseases

NEW ORLEANS, La. (Feb. 26, 2024) — From February 28, 2024 through March 1, 2024, the Global Alzheimer’s Platform Foundation (GAP), an organization dedicated to speeding and improving the delivery of Alzheimer’s clinical trials in pursuit of a cure, will convene more than 270 representatives from its network of 100+ clinical research sites, GAP-Net, at the InterContinental New Orleans in Louisiana.

The conference is an unparalleled gathering uniquely dedicated to improving clinical trials by bringing together clinical research leadership and executive teams from leading Alzheimer’s disease (AD) and Parkinson’s disease (PD) clinical trial sites across North America, pharmaceutical sponsors, Contract Research Organizations (CRO), and other partners and industry leaders dedicated to accelerating clinical research.

WHEN: February 28 – March 1

WHERE: InterContinental New Orleans in Louisiana

WHO: World class researchers, experts, industry partners, and business leaders from GAP-Net’s 100+ clinical trial sites across the United States and Canada, and more, including Dr. Susan Steen of Axiom Clinical Research, Dr. Jeffrey Cummings from University of Las Vegas, Dr. Howard Feldman of UC San Diego. Representatives from Biogen, the National Institute of Aging, BeingPatient, Eli Lily and Co., the Alzheimer’s Drug Discovery Foundation, Cleveland Clinic, Brigham and Women’s at Harvard, Eisai and Cognivue will also be in attendance.  GAP President John Dwyer will speak to the state of clinical trials and disease modifying therapies including deployment, and where the science is going next.

WHAT: The conference will fuel innovation through its unique collaboration, encouraging strong relationships to form while holding discussions around the future of Alzheimer’s disease research, the need for diversity in clinical trials, and the use of blood-based biomarkers. Additionally, the agenda will cover breakthroughs and updates in Parkinson’s disease research.

The GAP 2023 National Citizen Scientist Awards® will also be presented, as four clinical trial participants and study partners will be recognized for their time, passion, and dedication to helping find treatments and an eventual cure for Alzheimer’s and Parkinson’s diseases through their volunteerism.

The backdrop of the conference changes each year to reflect the capabilities of the network, its reach across the country, and the local impact that Alzheimer’s disease carries. In Louisiana, more than 92,000 people over the age of 65 have Alzheimer’s, a number that is expected to increase by 19.6% by 2025 and keep rising as the population ages[1]. Alzheimer’s is the most feared disease by people over the age of 50 years old, but researchers still have unique challenges in recruiting and retaining volunteers in Alzheimer’s disease studies. The GAP-Net Site Optimization Conference is a unique gathering for experts in the field to work together to collaborate and address this issue and more.

To learn more, GAP can arrange interviews with leading researchers from across the U.S. and Canada, as well as with GAP President John Dwyer and GAP leaders. They can speak to the latest breakthroughs in clinical research for Alzheimer’s disease and Parkinson’s disease, the challenges facing Alzheimer’s clinical trials, and strategies to overcome them in order to find a cure.

For more information on GAP, visit https://globalalzplatform.org/.


About GAP

The Global Alzheimer’s Platform Foundation® (GAP) is a patient-centered nonprofit organization dedicated to accelerating the delivery of innovative therapies for neurological disorders by reducing the duration and cost of clinical trials. Over 100 research centers around the world are part of the growing GAP Network (GAP-Net).

[1] https://www.alz.org/media/documents/alzheimers-facts-and-figures.pdf

To top